SANOFI

Tweet this page
<
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
>
Registration as it was on 16 Oct 2024
How to read and use this data card.
Download this datacard

Overview

Lobbying Costs

1,750,000€ - 1,999,999€

Financial year: Jan 2023 - Dec 2023

Lobbyists (Full time equivalent)

1.95 Fte (6)

Lobbyists with EP accreditation

4

High-level Commission meetings

34

Lobbying Costs over the years

  • Info

    SANOFI

    EU Transparency Register

    61291462764-77 First registered on 11 Dec 2009

    Goals / Remit

    Sanofi is dedicated to supporting people through their health challenges. We are a global biopharmaceutical company focused on human health. We prevent illness with vaccines, provide innovative treatments to fight pain and ease suffering. We stand by the few who suffer from rare diseases and the millions with long-term chronic conditions.
    We are driven by a unifying purpose and a common ambition. We believe our cutting-edge science and manufacturing, fueled by data and digital technologies, have the potential to transform the practice of medicine, turning the impossible into possible for millions of people around the world. With more than 100,000 people in 100 countries, we chase the miracles of science to improve people’s lives.

    Main EU files targeted

    - Revision of the general pharmaceutical legislation
    - Digital in Healthcare
    - AI Act
    - European Health Data Space
    - Urban wastewater treatment directive
    - Health Emergency Response Authority
    - pandemic preparedness
    - cross-border health threats
    - shortages of medicines
    - Critical Medicines Alliance
    - technical support instrument
    - MFF
    - manufacturing/value-chain of pharmaceuticals/industrial strategy
    - EU Vaccines policies and vaccine-related activities/prevention
    - European green deal agenda
    - EU pharmaceutical strategy
    - EU Competitiveness and Industrial policy, biotech act
    - state aid policy/IPCEI
    - Economic Security Strategy
    - EU Research policy / framework program/IHI
    - EU options for improving access to medicines
    - Health Technology Assessment Regulation
    - Paediatric Regulation
    - Pharmaceuticals in the environment
    - Protection of animals used for scientific purposes Directive
    - Regulation on Orphan Medicinal Products
    - climate policy
    - Reach
    - Trade Agreements
    - Self-care

    Related to above listed topics, senior leaders and experts of Sanofi participate intuitu personae in working groups of the Conseil de Cooperation Economique (CCE), without Sanofi being a member of the CCE.

    Address

    Head Office
    SANOFI GROUPE46 avenue de la Grande Armée
    Paris 75017
    FRANCE
    EU Office
    14 rue de la Science
    Brussels 1000
    BELGIUM

    Website

  • People

    Total lobbyists declared

    6

    Employment timeLobbyists
    75%1
    50%1
    25%2
    10%2

    Lobbyists (Full time equivalent)

    1.95

    Lobbyists with EP accreditation

    All Lobbyists with EP accreditation over time

    4 accreditations were / are live (in bold) for the selected state of 23 Nov 2024

    Name Start date End Date
    Mark John Canavan 16 Oct 2024 16 Oct 2025
    Florence Baron-Papillon 16 Oct 2024 16 Oct 2025
    Milena van Iterson 16 Oct 2024 16 Oct 2025
    David Elvira Martinez 23 Jul 2024 23 Jul 2025
    Florence BARON PAPILLON 09 Feb 2024 04 Oct 2024
    Jordan RANKIN 09 Mar 2024 04 Oct 2024
    Mark CANAVAN 05 Mar 2024 04 Oct 2024
    Milena RICHTER 09 Nov 2023 04 Oct 2024
    Marie Helene FANDEL 18 Nov 2022 25 Oct 2023
    Milena RICHTER 13 Oct 2022 13 Oct 2023
    Milena RICHTER 18 Oct 2019 17 Oct 2020
    Ms Clara ZACHMANN 01 Oct 2019 01 Oct 2020
    Mr Jérémy Alain MICHEL 05 Oct 2018 05 Oct 2019
    Milena RICHTER 05 Oct 2018 05 Oct 2019
    Ms Clara ZACHMANN 19 Sep 2018 19 Sep 2019
    Ms Katharina Lotz 17 Apr 2018 17 Apr 2019
    Mr Jérémy Alain MICHEL 30 Oct 2017 05 Oct 2018
    Milena RICHTER 30 Oct 2017 05 Oct 2018
    Ms Clara ZACHMANN 16 Sep 2017 15 Sep 2018
    Mr Darren KINSELLA 24 Mar 2017 03 Jan 2018
    Milena RICHTER 19 Nov 2016 30 Oct 2017
    Mr Jérémy Alain MICHEL 17 Nov 2016 30 Oct 2017
    Mr Darren KINSELLA 23 Mar 2016 22 Mar 2017
    Ms Corinne ASSOULINE-DUGUAY 05 Mar 2016 04 Mar 2017
    Mr Jérémy Alain MICHEL 18 Nov 2015 16 Nov 2016
    Milena RICHTER 18 Nov 2015 16 Nov 2016
    Mr Hannu JOUHKI 10 Mar 2015 27 Feb 2016
    Ms Corinne ASSOULINE-DUGUAY 27 Feb 2015 25 Feb 2016
    Ms Corinne ASSOULINE-DUGUAY 21 Feb 2014 03 Mar 2015
    Milena RICHTER 19 Nov 2014 17 Nov 2015
    Mr Jérémy Alain MICHEL 19 Nov 2014 17 Nov 2015
    Milena RICHTER 19 Nov 2014 27 Jan 2015
    Mr Hannu JOUHKI 04 Mar 2014 03 Mar 2015
    Mrs Corinne ASSOULINE-DUGUAY 21 Feb 2014 27 Jan 2015
    Mr Jérémy Alain MICHEL 09 Nov 2013 08 Nov 2014
    Milena RICHTER 18 May 2013 17 May 2014
    Mrs Corinne ASSOULINE épouse DUGUAY 28 Feb 2013 19 Feb 2014
    Mr Erick Denis François Robert TYSSIER 22 Jan 2013 13 Oct 2013
    Mrs Danuta Marianna RYDLEWSKA 23 Jan 2013 08 Aug 2013
    Mr Jérémy Alain MICHEL 22 Jan 2013 09 Nov 2013
    Mr Erick Denis François Robert TYSSIER 22 Feb 2012 08 Feb 2013
    Mrs Danuta Marianna RYDLEWSKA 01 Feb 2012 08 Feb 2013
    Mr Jérémy Alain MICHEL 01 Feb 2012 08 Feb 2013
    Mr Grégory LAMORY 02 Feb 2012 08 Feb 2013

    Complementary Information

    None declared

    Person in charge of EU relations

    Data not provided by Register Secretariat due to GDPR

    Person with legal responsibility

    Data not provided by Register Secretariat due to GDPR

  • Categories

    Category

    Companies & groups

  • Networking

    Affiliation

    Professional associations:
    AESGP - Association of the European Self-Medication Industry
    AFEP (French Association of Private Companies)
    EFPIA - European Federation of Pharmaceutical Industries and Associations)
    IPA - International Probiotics Association
    FSE (Food Supplements Europe)
    Vaccines Europe
    EUCOPE
    France Industrie
    Wirtschaftsforum

    Think tanks :
    Science Business

    Member organisations

    None declared

  • Financial Data

    Interests represented

    Promotes their own interests or the collective interests of their members

    Closed financial year

    Jan 2023 - Dec 2023

    Lobbying costs for closed financial year

    1,750,000€ - 1,999,999€

    Major contributions in closed year

    None declared

    Intermediaries for closed year

    NameAmount
    darwin associates 100,000€ - 199,999€
    bcw 25,000€ - 49,999€
    weber shandwick 200,000€ - 299,999€
    fipra 50,000€ - 99,999€
    fti 10,000€ - 24,999€
    acumen 100,000€ - 199,999€

    Intermediaries for current year

    Name
    fti consulting
    bcw
    darwin associates
    acumen
    burson marsteller

    Closed year Costs

    1,750,000€ - 1,999,999€

    Other financial info

    Sanofi is a global company with a diversified portfolio of medicines and vaccines covering specialty care, general medicines, immunization and self-care. This declaration includes costs relevant to the Transparency Register that are incurred by Sanofi beyond our EU Office, i.e. expenses linked to our business units’ activities that fall within the scope of the register. This includes position papers and articles, background research, events etc, including costs incurred by intermediary contracts. We have also included the percentage calculation of time spent on activities covered by the Register by employees of the company based outside our EU Office in Brussels.

  • EU Structures

    Groups (European Commission)

    None declared

    Groups (European Parliament)

    N/A

    Communication activities

    Sanofi communications activities included the organisation of several events, sponsorships etc in 2022 such as:

    Sponsorship of the European Public Procurement Summit 2022:
    https://www.healthprocsummit.com/health-procurement-summit-2022

    "Chronically Underserved" event:
    https://www.politico.eu/event/politicos-spotlight-chronically-undeserved-bridging-the-gap-in-chronic-care/

    Participation and sponsorship of a consensus panel by EAPM:
    https://www.euapm.eu/pdf/EAPM_Consensus_Panel_Series_Pharmaceutical_Legislation_-_The_need_for_pragmatism_–_and_how_to_make_it_happen.pdf

    Support to the Together4RD partnership
    https://together4rd.eu/what-is-together4rd/structure-and-sponsors/

    Other activities

    None declared

  • Meetings

    Meetings

    34 meetings found. Download meetings

    The list below only covers meetings held since November 2014 with commissioners, their cabinet members or directors-general at the European Commission; other lobby meetings with lower-level staff may have taken place, but the European Commission doesn't proactively publish information about these meetings. For more information about which commissioner is responsible for which portfolio, check out this link: https://commissioners.ec.europa.eu/index_en All information below comes from European Commission web pages.

    1 July 2024: We have noted that some meetings are appearing in duplicate, ie. some meetings seem to be listed twice. This seems to be because the Commission changes some element of a meeting data after the meeting has first been listed, which causes LobbyFacts to register it as a new meeting. We are investigating further.

    • Date 30 Sep 2024 Location Mexico
      Subject The objective of the lunch is to gather the views of key representatives from the EU private sector regarding the present situation in Mexico and prospects under the new administration, notably from an economic perspective, in an open dialogue.
      Cabinet Cabinet of High Representative Josep Borrell Fontelles
      Attending
      • Josep Borrell Fontelles (High Representative)
      Other Lobbyists
    • Date 19 Mar 2024 Location Brussels
      Subject industrial competitiveness of pharma sector
      Cabinet Cabinet of Commissioner Thierry Breton
      Attending
      • Thierry Breton (Commissioner)
    • Date 05 Mar 2024 Location Brussels
      Subject Discussion on IPCEI
      DG Competition
      Attending
      • Olivier Guersent (Director-General)
    • Date 17 Jan 2024 Location Davos
      Subject Meeting with Mr Roy Papatheodorou, SANOFI Executive Vice President and General Counsel
      Cabinet Cabinet of Commissioner Stella Kyriakides
      Attending
      • Stella Kyriakides (Commissioner)
      • Giorgios Rossides (Cabinet member)
    • Date 14 Oct 2022 Location Brussels, Belgium
      Subject Pharmaceutical investments, implementation of the Pharma Strategy
      Cabinet Cabinet of Commissioner Thierry Breton
      Portfolio Internal Market
      Attending
      • Eszter Batta (Cabinet member)
    • Date 07 Sep 2022 Location Webex
      Subject Meeting with the German Pharmaceutical Association and Sanofi to discuss the pharmaceutical reform
      Cabinet Cabinet of Commissioner Stella Kyriakides
      Portfolio Health
      Attending
      • Karolina Herbout-Borczak (Cabinet member)
      Other Lobbyists
    • Date 10 Jun 2022 Location Videoconference
      Subject Discussion on stragegic foresight
      Cabinet Cabinet of Vice-President Maroš Šefčovič
      Portfolio Energy Union
      Attending
      • Dimitri Lorenzani (Cabinet member)
    • Date 10 Jun 2022 Location Videoconference
      Subject Discussion on stragegic foresight
      Cabinet Cabinet of Vice-President Maroš Šefčovič
      Portfolio Interinstitutional Relations and Foresight
      Attending
      • Dimitri Lorenzani (Cabinet member)
    • Date 08 Jun 2022 Location call
      Subject health industrial ecosystem, HERA and green transition
      Cabinet Cabinet of Commissioner Thierry Breton
      Portfolio Internal Market
      Attending
      • Maurits-Jan Prinz (Cabinet member)
    • Date 03 Feb 2022 Location Videoconference
      Subject Initiatives in the health industrial ecosystem
      Cabinet Cabinet of Commissioner Thierry Breton
      Portfolio Internal Market
      Attending
      • Maurits-Jan Prinz (Cabinet member)
    • Date 26 Oct 2021 Location Brussels
      Subject Pharmaceutical sector – trade related issues
      Cabinet Cabinet of Executive Vice-President Valdis Dombrovskis
      Portfolio An Economy that Works for People
      Attending
      • Elina Melngaile (Cabinet member)
      • Kevin Keary (Cabinet member)
      • Caroline Boeshertz (Cabinet member)
      Other Lobbyists
    • Date 16 Jun 2021 Location online
      Subject Supply chains for medicines
      Cabinet Cabinet of Vice-President Margaritis Schinas
      Portfolio Promoting the European Way of Life
      Attending
      • Maria Luisa Llano Cardenal (Cabinet member)
      • Margaritis Schinas (Vice-President)
      Other Lobbyists
    • Date 26 Mar 2021 Location Videoconference
      Subject Health in the industry policy update
      Cabinet Cabinet of Commissioner Thierry Breton
      Portfolio Internal Market
      Attending
      • Eszter Batta (Cabinet member)
    • Date 31 Jan 2021 Location Videoconference
      Subject Meeting with CEOs of the pharmaceutical companies with which the Commission has signed Advance Purchase Agreements
      Cabinet Cabinet of President Ursula von der Leyen
      Portfolio President
      Attending
      • Ursula von der Leyen (President)
      Other Lobbyists
    • Date 23 Nov 2020 Location Brussels (WEBEX)
      Subject Alliances
      Cabinet Cabinet of President Ursula von der Leyen
      Portfolio President
      Attending
      • Kurt Vandenberghe (Cabinet member)
    • Date 16 Nov 2020 Location Videoconference
      Subject Pharmaceutical manufacturing in the EU
      Cabinet Cabinet of Commissioner Thierry Breton
      Portfolio Internal Market
      Attending
      • Eszter Batta (Cabinet member)
      • Thierry Breton (Commissioner)
    • Date 13 Oct 2020 Location Videoconference
      Subject Pharmaceutical manufacturing in the EU
      Cabinet Cabinet of Commissioner Thierry Breton
      Portfolio Internal Market
      Attending
      • Thierry Breton (Commissioner)
      • Eszter Batta (Cabinet member)
    • Date 25 May 2020 Location Videoconference
      Subject Perspectives on the fight against COVID-19
      Cabinet Cabinet of Commissioner Thierry Breton
      Portfolio Internal Market
      Attending
      • Thierry Breton (Commissioner)
    • Date 06 Apr 2020 Location Videoconference
      Subject Digitisation of healthcare and innovative e-health solutions.
      Cabinet Cabinet of Commissioner Thierry Breton
      Portfolio Internal Market
      Attending
      • Thierry Breton (Commissioner)
      Other Lobbyists
    • Date 21 Feb 2018 Location Brussels
      Subject HTA; Supplementary Protection Certificates (SPC)
      Cabinet Cabinet of Commissioner Vytenis Andriukaitis
      Portfolio Health &amp; Food Safety
      Attending
      • Annika Nowak (Cabinet member)
      Other Lobbyists
    • Date 25 Jan 2018 Location Brussels
      Subject European patent protection
      Cabinet Cabinet of Commissioner Pierre Moscovici
      Portfolio Economic and Financial Affairs, Taxation and Customs
      Attending
      • Lucie Mattera (Cabinet member)
      Other Lobbyists
    • Date 24 Jan 2018 Location Brussels
      Subject Digital Healthcare
      Cabinet Cabinet of Commissioner Mariya Gabriel
      Portfolio Digital Economy and Society
      Attending
      • Manuel Mateo-Goyet (Cabinet member)
    • Date 24 Jan 2018 Location BRUSSELS
      Subject HTA; E-Health
      Cabinet Cabinet of Commissioner Vytenis Andriukaitis
      Portfolio Health &amp; Food Safety
      Attending
      • Annika Nowak (Cabinet member)
    • Date 10 Oct 2017 Location Brussels
      Subject Life Science in the EU
      Cabinet Cabinet of First Vice-President Frans Timmermans
      Portfolio Better Regulation, Interinstitutional Relations, the Rule of Law and the Charter of Fundamental Rights
      Attending
      • Bernardus Smulders (Cabinet member)
    • Date 18 Apr 2016 Location Brussels, Belgium
      Subject Access to health care including pharmaceuticals in developing countries
      Cabinet Cabinet of Vice-President Neven Mimica
      Portfolio International Cooperation &amp; Development
      Attending
      • Nils Behrndt (Cabinet member)
    • Date 18 Apr 2016 Location Berlaymont
      Subject EPSC, Interinstitutional relations
      Cabinet Cabinet of President Jean-Claude Juncker
      Portfolio President
      Attending
      • Clara Martinez Alberola (Cabinet member)
    • Date 17 Mar 2016 Location Brussels
      Subject AMR, HTA
      Cabinet Cabinet of Commissioner Vytenis Andriukaitis
      Portfolio Health &amp; Food Safety
      Attending
      • Annika Nowak (Cabinet member)
    • Date 02 Jul 2015 Location Brussels
      Subject vaccinations
      Cabinet Cabinet of Commissioner Vytenis Andriukaitis
      Portfolio Health &amp; Food Safety
      Attending
      • Vytenis Andriukaitis (Commissioner)
      • Paula Duarte Gaspar (Cabinet member)
    • Date 03 Jun 2015 Location Brussels
      Subject New College and Better Regulation
      DG Communications Networks, Content and Technology
      Attending
      • Robert Madelin (Director-General)
      Other Lobbyists
    • Date 07 May 2015 Location Brussels
      Subject Implementation Council Conclusions on Vaccination
      Cabinet Cabinet of Commissioner Carlos Moedas
      Portfolio Research, Science and Innovation
      Attending
      • Giulia Del Brenna (Cabinet member)
    • Date 27 Mar 2015 Location Berlaymont
      Subject How to strengthen a European coherent approach with focus on ERA development, ways to reduce the fragmented approach in Europe for evaluation the value of new medicines for improved access for the patient, and means of creating a more dynamic environment for medicine development in Europe and driving an ambitious agenda allowing the European life sciences sector to remain competetive on a global scale.
      Cabinet Cabinet of President Jean-Claude Juncker
      Portfolio President
      Attending
      • Clara Martinez Alberola (Cabinet member)
    • Date 19 Mar 2015 Location Brussels
      Subject New Commission, Investment plan, TTIP
      Cabinet Cabinet of Vice-President Jyrki Katainen
      Portfolio Jobs, Growth, Investment and Competitiveness
      Attending
      • Juho Romakkaniemi (Cabinet member)
    • Date 19 Feb 2015 Location Berlaymont
      Subject Exchange of views in the perspective to present of Health & Growth and to discuss ERA, medicine development and its access for the patient
      Cabinet Cabinet of President Jean-Claude Juncker
      Portfolio President
      Attending
      • Clara Martinez Alberola (Cabinet member)
    • Date 21 Jan 2015 Location Brussels Belgium
      Subject A reflection on how Europe can move towards the development of a genuine European Research Area, benefiting from closer cooperation between the private and the academic and public sectors and better exploit the links between fundamental and translational research.
      Cabinet Cabinet of Commissioner Elżbieta Bieńkowska
      Portfolio Internal Market, Industry, Entrepreneurship and SMEs
      Attending
      • Rolf Carsten Bermig (Cabinet member)
Download this datacard